ITCI - Intra-Cellular Therapies, Inc.
| Previous Close | 9.81 |
| Open | 9.83 |
| Bid | 0.00 x 1000 |
| Ask | 0.00 x 800 |
| Day's Range | 9.82 - 10.36 |
| 52 Week Range | 6.75 - 16.76 |
| Volume | 601,788 |
| Avg. Volume | 899,285 |
| Market Cap | 563.662M |
| Beta (3Y Monthly) | 1.22 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.69 |
| Earnings Date | Nov 5, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 25.22 |
- GlobeNewswire
Intra-Cellular Therapies to Present Data on Lumateperone and ITI-333 at the 58th Annual Meeting of the American College of Neuropsychopharmacology
Intra-Cellular Therapies, Inc. (ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that the Company will be presenting at the 58th Annual Meeting of the American College of Neuropsychopharmacology (ACNP) to be held in Hollywood, FL, December 8-11, 2019. Intra-Cellular Therapies will be presenting the following posters and presentations at ACNP, which will include results from Study 404, a Phase 3 clinical trial evaluating lumateperone for the treatment of bipolar depression, as well as new data from the schizophrenia clinical program including the long-term safety study. Lumateperone is a novel investigational drug currently under review by the FDA as a potential treatment for adults with schizophrenia.
- Thomson Reuters StreetEvents
Edited Transcript of ITCI earnings conference call or presentation 5-Nov-19 1:30pm GMT
Q3 2019 Intra-Cellular Therapies Inc Earnings Call
- Zacks
Options Traders Expect Huge Moves in Intra-Cellular Therapies (ITCI) Stock
Investors need to pay close attention to Intra-Cellular Therapies (ITCI) stock based on the movements in the options market lately.
- Zacks
Top Ranked Momentum Stocks to Buy for November 11th
Top Ranked Momentum Stocks to Buy for November 11th
- Insider Monkey
Hedge Funds Have Never Been Less Bullish On Intra-Cellular Therapies Inc (ITCI)
We are still in an overall bull market and many stocks that smart money investors were piling into surged through October 17th. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 45% and 39% respectively. Hedge funds' top 3 stock picks returned 34.4% this year and beat the S&P […]
- GlobeNewswire
Intra-Cellular Therapies Provides Corporate Update and Reports Third Quarter 2019 Financial Results
NEW YORK, Nov. 05, 2019 -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system.
- TipRanks
3 Hot Biotech Stocks With 100% Street Support
For more risk-tolerant investors, biotechs are screaming buys. This space is consistently on the Street’s radar as a single catalyst such as a positive FDA advisory committee (AdCom) outcome or promising trial results can send shares through the roof. For example, Agile Therapeutics (AGRX) saw share prices skyrocket 223% in just one day after an FDA AdCom vote resulted in an approval recommendation for its Twirla contraceptive patch. However, the reverse also holds true meaning that biotech stocks carry their fair share of risk. So how are investors supposed to pick the biotech names most poised to outperform the market? We suggest looking to Wall Street analysts.While the consensus on a given stock can be resoundingly mixed, when all of the analysts covering the stock are onboard it’s a signal that can’t be ignored. With this in mind, we used the TipRanks Stock Screener to narrow down 3 biotechs that have garnered exclusively bullish calls over the last three months. Not to mention each of the stocks on our list boast huge upside potential from the current share price. Let’s get started. Intra-Cellular Therapies (ITCI)Intra-Cellular wants to help the millions of people living with mental health conditions around the world. With one and five people being affected by mental illness in the U.S. alone, the implications of the biotech’s unique treatments are nothing short of monumental.Its lead product candidate, lumateperone, was designed to provide selective and simultaneous modulation of three neurotransmitter pathways implicated in severe mental illness, namely serotonin, dopamine and glutamate. While the FDA had previously announced that it would hold an AdCom for the therapy’s use in treating schizophrenia, the panel was cancelled after ITCI submitted additional nonclinical data. This data suggests that the drug is metabolized differently in humans and animals, and thus any safety issues witnessed in animals have no bearing on its safety for human use.Ahead of the FDA’s approval decision scheduled for on or before December 27, Cantor Fitzgerald analyst Charles Duncan is impressed. He believes that ITCI’s “rapid” turnaround before the action date should work in the company’s favor. In addition, he views the FDA's decision to not hold a panel meeting as suggesting that the new drug application data package is “robust”. All of this lends itself to the five-star analyst’s conclusion that the second half of 2019 and early 2020 will be "transformational" for the biotech, prompting him to reiterate his Buy rating. With a $27 price target, the upside potential comes in at 181%. (To watch Duncan’s track record, click here) Like Duncan, the rest of the Street is bullish on ITCI. Based on the 6 Buy recommendations assigned in the last three months and 158% upside potential, it’s clear this ‘Strong Buy’ biotech has a lot to brag about. (See Intra-Cellular stock analysis on TipRanks) Moderna Inc. (MRNA)Moderna is revolutionizing the way we treat a wide variety of diseases through its use of messenger RNA (mRNA). mRNA is the set of instructions that cells use to make proteins and send them to different parts of the body. With a multitude of programs in development, one top analyst warns investors not to miss out on this unique opportunity. Roth Capital’s Yasmeen Rahimi argues that MRNA is well funded, and is thus capable of bringing its 16 clinical programs to their next turning points. Her conclusion is not only based on the company’s continued clinical and preclinical progress, but also recent positive developments.On October 22, MRNA announced that the FDA had given its investigational mRNA therapeutic for propionic acidemia (PA), mRNA-3927, Fast Track designation. PA is caused when the body is unable to break down proteins and fats, leading to the buildup of harmful chemicals. As there currently aren’t any therapies for the condition on the market, there is a desperate need for a treatment. It should also be noted that this designation bodes well for MRNA as it enables early and frequent communication with the FDA and a rolling submission of the marketing application. All of the above factors played into Rahimi’s decision to initiate her MRNA coverage with a bullish call. At her price target of $24, shares could climb 53% higher over the next twelve months. (To watch Rahimi’s track record, click here) As only Buy ratings have been issued in the last ten months, it’s no question that this biotech is a ‘Strong Buy’. Not to mention its $31 average price target puts the upside potential at 83%. (See Moderna stock analysis on TipRanks) Revance Therapeutics, Inc. (RVNC)Revance Therapeutics is using innovative techniques to develop a new category of neuromodulators for both aesthetic and therapeutic treatments. Neuromodulators include injectable and non-injectable therapies that can be used to treat an array of conditions like persistent pain, spasticity, movement disorders, epilepsy as well as several others. Following its third quarter earnings results, many analysts believe that RVNC is set to take off.On November 4, the company stated that it’s on track to submit its FDA Biologics License Application (BLA) for its lead candidate, DaxibotulinumtoxinA for Injection (DAXI), to treat glabellar lines later this month. Adding to the good news, RVNC completed enrollment for the ASPEN-1 Phase 3 clinical trial for DAXI to treat cervical dystonia (CD), a condition that causes painful neck spasms. While investors had some concerns regarding RVNC’s collaboration with Mylan (MYL), Needham analyst Serge Belanger tells investors that his bullish thesis remains firmly intact. “One concern for RVNC investors following the recent announcement of the proposed Mylan/Upjohn (Pfizer) tie-up involved the potential impact of the transaction on the ongoing collaboration with Mylan to develop a biosimilar Botox. RVNC issued an 8K this morning announcing an amendment to the collaboration that extends the clock on MYL's opt-in decision to 4/30/2020, in return for a $5 million payment. The additional time should allow MYL and Upjohn to conduct a portfolio review ahead of transaction close expected in mid-2020,” he explained. Along with his Buy rating, Belanger’s price target implies shares could jump 102% over the next twelve months. (To watch Belanger’s track record, click here) Similarly, the rest of the Street likes what it’s seeing. With 100% of analysts backing the biotech, RVNC is a ‘Strong Buy’. In addition, its $33 average price target suggests 111% upside from the current share price. (See Revance Therapeutics stock analysis on TipRanks)
- Zacks
Intra-Cellular Therapies Shares March Higher, Can It Continue?
As of late, it has definitely been a great time to be an investor Intra-Cellular Therapies.
- GlobeNewswire
Intra-Cellular Therapies to Host Third Quarter 2019 Financial Results Conference Call and Webcast
Intra-Cellular Therapies, Inc. (ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that it will host a conference call and live webcast discussion at 8:30 a.m. Eastern Time on Tuesday, November 5, 2019, to provide a corporate update and discuss details of the Company's financial results for the quarter ended September 30, 2019. The live and archived webcast can be accessed under "Press Releases & Events" in the Investor Relations section of the Company's website at www.intracellulartherapies.com. Intra-Cellular Therapies is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson's and Alzheimer's disease.
- Simply Wall St.
Companies Like Intra-Cellular Therapies (NASDAQ:ITCI) Are In A Position To Invest In Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
- GlobeNewswire
Intra-Cellular Therapies to Present at the 2019 Cantor Global Healthcare Conference
Intra-Cellular Therapies, Inc. (ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the 2019 Cantor Global Healthcare Conference in New York. The live and archived webcast can be accessed under "Press Releases & Events" in the Investor Relations section of the Company's website at www.intracellulartherapies.com. Intra-Cellular Therapies is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson's and Alzheimer's disease.
- Zacks
Are Options Traders Betting on a Big Move in Intra-Cellular Therapies (ITCI) Stock?
Investors need to pay close attention to Intra-Cellular Therapies (ITCI) stock based on the movements in the options market lately.
- Simply Wall St.
Who Has Been Buying Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares?
We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be...
- GlobeNewswire
Intra-Cellular Therapies Announces Progression to Higher Dose Cohort in ITI-214 Translational Medicine Study in Patients with Heart Failure
Intra-Cellular Therapies, Inc. (ITCI) today announced the successful completion of the second dose cohort (single dose of 30 mg administered orally) in Study ITI-214-104 (Study ‘104), a proof-of-mechanism, translational medicine study of ITI-214, a novel phosphodiesterase-1 (PDE1) inhibitor, in patients with chronic heart failure. Clinical conduct of the third and last cohort, 90 mg, is now ongoing following review of safety and tolerability data from the 30 mg dose cohort, where no safety concerns were identified. Initiation of Study 104 followed findings that ITI-214 improved cardiac output through a different mechanism of action than available heart failure therapies. These findings in a preclinical model of heart failure were published by researchers at Johns Hopkins University and ITCI scientists in the journal Circulation. Currently available heart failure drugs that strengthen heart contractions, such as the PDE3 inhibitors (amrinone and milrinone) and ß-adrenergic agonists (dobutamine), increase calcium entry into cardiac muscle cells and have potentially dangerous complications, such as irregular heartbeats.
- Zacks
6 Small Drug Stocks in Focus Ahead of World Alzheimer's Day
Here we discuss six small-cap companies with promising candidates in their pipeline for Alzheimer's disease.
- Benzinga
FDA: No Adcom Meeting For Intra-Cellular's Schizophrenia Drug
Intra-Cellular Therapies Inc (NASDAQ: ITCI) shares were volatile Tuesday after the actively traded, small-cap biotech announced that the FDA has informed the company that it does not plan to hold an Advisory Committee meeting with regard to the review of the company's NDA for lumateperone. Lumateperone is the company's investigational asset that is being evaluated for the treatment of schizophrenia. The company said it has recently submitted to the FDA the results of non-clinical analyses related to toxicology findings in animal studies.
- GlobeNewswire
Intra-Cellular Therapies Provides Lumateperone Regulatory Update
Intra-Cellular Therapies, Inc. (ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that it does not have plans to schedule an Advisory Committee meeting in connection with its review of the Company’s New Drug Application (NDA) for lumateperone for the treatment of schizophrenia. The lumateperone Prescription Drug User Fee Act (PDUFA) goal date is December 27, 2019.
- Simply Wall St.
How Should Investors React To Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) CEO Pay?
Sharon Mates has been the CEO of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) since 2013. First, this article will...
- Motley Fool
5 Biggest New Drug Approvals Potentially on the Way in 2019
FDA approvals for these drugs could translate to billions of dollars for a few companies.
- GlobeNewswire
Intra-Cellular Therapies Provides Corporate Update and Reports Second Quarter 2019 Financial Results
NEW YORK, Aug. 07, 2019 -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system.
- GlobeNewswire
Intra-Cellular Therapies to Present at the Canaccord Genuity 39th Annual Growth Conference
Intra-Cellular Therapies, Inc. (ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the Canaccord Genuity 39th Annual Growth Conference in Boston. The live and archived webcast can be accessed under "Press Releases & Events" in the Investor Relations section of the Company's website at www.intracellulartherapies.com. Intra-Cellular Therapies is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson's and Alzheimer's disease.
- GlobeNewswire
Intra-Cellular Therapies to Host Conference Call to Provide Regulatory Update Following Recent Meeting with FDA
Agreement reached with FDA on submission of additional non-clinical information for NDA review of lumateperone for the treatment of schizophreniaLumateperone PDUFA goal date.
- Zacks
Biotech Stock Roundup: BIIB Q2 Earnings Top & CELG's Otezla Label Expanded
Key highlights of the past week include earnings update, collaborations and other pipeline news.
- GlobeNewswire
Intra-Cellular Therapies Provides Update on FDA Advisory Committee Meeting for Lumateperone for the Treatment of Schizophrenia
Intra-Cellular Therapies, Inc. (ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has cancelled the Psychopharmacologic Drugs Advisory Committee meeting scheduled for July 31, 2019 to discuss the New Drug Application (NDA) for lumateperone for the treatment of schizophrenia. The Company has a meeting scheduled with the FDA shortly and will provide an update following the meeting.
- Motley Fool
Why PulteGroup, Intra-Cellular Therapies, and Clear Channel Outdoor Slumped Today
Bad news in several forms hit some stocks despite a strong session for the overall market.
